GLP-1 Drug Manufacturers for Weight Loss | PlexusDx

Five major pharmaceutical companies currently produce FDA-approved GLP-1 medications for weight loss: Novo Nordisk (semaglutide, tirzepatide), Eli Lilly (tirzepatide, retatrutide), Viking Therapeutics, Structure Therapeutics, and Amgen. Each manufacturer brings different formulations, dosing schedules, and clinical efficacy profiles to the market.

Beyond brand names and manufacturers, your individual response to GLP-1 therapy depends on genetics, metabolic biomarkers, and peptide receptor sensitivity. PlexusDx's precision-wellness approach helps you understand your metabolic predispositions, enabling more informed conversations with providers about which GLP-1 option may align with your physiology.

Major GLP-1 Manufacturers and Their Product Lines

Novo Nordisk leads the GLP-1 market with semaglutide (Ozempic for diabetes, Wegovy for weight loss) and tirzepatide under license partnerships. Semaglutide is administered once weekly via injection or daily oral formulation. Clinical trials show approximately 15-22% weight reduction over 68 weeks with semaglutide in weight-management studies.

Eli Lilly manufactures tirzepatide (Zepbound for weight loss, Mounjaro for diabetes), a dual GIP/GLP-1 receptor agonist showing superior weight loss compared to semaglutide monotherapy in head-to-head trials. Eli Lilly also developed retatrutide, a triple-hormone receptor agonist (GLP-1/GIP/glucagon) currently in late-stage trials, with interim data suggesting up to 24% weight reduction.

Manufacturer Comparison: Formulation, Mechanism, and Clinical Evidence

Each manufacturer's GLP-1 product differs in receptor selectivity, pharmacokinetics, and demonstrated efficacy. Direct comparisons help contextualize why provider selection depends on individual metabolic factors, not brand alone. The table below outlines key clinical distinctions across major products.

How Genetic Factors Influence GLP-1 Response Beyond Manufacturer

Your GLP-1 receptor gene variants (GLP1R rs6923761) and GIP receptor polymorphisms (GIPR rs1800437) may predict how your body responds to specific receptor agonist formulations. These predispositions don't determine outcomes but can provide context for why certain medications work better for some patients than others.

Weight-regulation genes like FTO rs9939609 and MC4R rs17782313 influence baseline metabolic dysfunction and appetite signaling. Understanding your genetic predispositions in peptide pathways allows providers to tailor GLP-1 selection more strategically, rather than defaulting to whichever manufacturer is most marketed.

Safety, Eligibility, and Clinical Decision-Making with Your Provider

GLP-1 medications carry shared side effects across manufacturers: nausea, vomiting, constipation, and gastrointestinal upset, particularly during dose escalation. Contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe renal/hepatic impairment. Your healthcare provider must evaluate your medical history regardless of which manufacturer's product you consider.

Provider selection of a GLP-1 medication should balance efficacy data, your metabolic profile, genetic predispositions, affordability, and injection/oral preference. Compounded formulations from licensed 503A pharmacies offer additional cost-effective options. A qualified provider can help interpret your biomarker and genetic test results in context of manufacturer choice, ensuring alignment with your health goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context on your predispositions in GLP1R, GIPR, and weight-regulation gene variants (FTO, MC4R). This information can support a more informed conversation with your provider about which GLP-1 manufacturer and formulation may align best with your metabolic genetics.

The genetic test reveals predispositions in peptide receptor pathways—not exact medication response. Variants like GLP1R rs6923761 and GIPR rs1800437 can inform provider discussions about dual-agonist versus single-agonist formulations, but results should be interpreted with a qualified healthcare provider who understands your complete clinical picture.

PlexusDx compounded semaglutide and tirzepatide injections offer cost-effective alternatives to branded medications, starting at $149/mo per month from licensed 503A compounding pharmacies. Combined with genetic testing and provider guidance, this precision approach enables personalized GLP-1 selection informed by your peptide pathway predispositions, not manufacturer marketing alone.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

• Glp 1 Drugs For Weight Loss
• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss